Most COVID-19 trial preprints were eventually published, and the conclusions mostly stayed the same

During the pandemic, preprints helped make clinical trial results available as quickly as possible, and now researchers have found that most preprints of COVID-19 clinical trials ended up being published in a peer-reviewed journal. The researchers found that preprint studies with smaller numbers of participants (sample size) and higher risk of bias were less likely to be published. They also found that, although there were differences in the reported outcomes, analyses and results between the preprint and final publication, the main conclusions remained the same for the majority of studies.